18
May
2015

Zigging Away From the Herd: Lilly’s Road-Less-Traveled R&D Strategy

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

‘Pharmaphobia’ Pushes Back Against Anti-Industry Crusade, But Comes Up Short
Molecular Information Companies, One Way or Another, Find Value in Genomics
Data From Texas: VCs, Still Mostly Underwater, Ride Stocks As Long As Possible
Bad Behaviors Creeping Into Biotech During the Boom